Matthias Zunhammer1, Magnus Gerardi2, Ulrike Bingel2. 1. Klinik für Neurologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Germany. matthias.zunhammer@uk-essen.de. 2. Klinik für Neurologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Germany.
Abstract
RATIONALE: Better means to control placebo effects are key to optimizing treatment outcomes. Dopamine-based reward and learning mechanisms have been hypothesized to drive placebo effects. Here, we tested whether dopamine augmentation can modulate learned placebo effects. METHODS: We performed a randomized, double-blind parallel group study with 70 healthy adult participants to test whether a single oral dose of the dopamine precursor levodopa/carbidopa (100/25 mg) administered before the acquisition of conditioned placebo analgesia enhances the placebo response in an established experimental placebo model using heat pain. RESULTS: Overall, the observed levels of placebo analgesia in our sample were low and not statistically significant. Levodopa, compared to placebo, only led to a marginal increase in placebo analgesia. Female participants tended to show larger placebo responses than male participants. Within the female subgroup, levodopa showed small-to-moderate effects on placebo analgesia; however, this effect was not statistically significant. CONCLUSIONS: In summary, the present study could not provide evidence for a placebo augmenting effect of levodopa-enhanced dopamine levels in healthy subjects. Further studies are needed to elucidate whether placebo enhancement can be achieved through dopamine augmentation.
RCT Entities:
RATIONALE: Better means to control placebo effects are key to optimizing treatment outcomes. Dopamine-based reward and learning mechanisms have been hypothesized to drive placebo effects. Here, we tested whether dopamine augmentation can modulate learned placebo effects. METHODS: We performed a randomized, double-blind parallel group study with 70 healthy adult participants to test whether a single oral dose of the dopamine precursor levodopa/carbidopa (100/25 mg) administered before the acquisition of conditioned placebo analgesia enhances the placebo response in an established experimental placebo model using heat pain. RESULTS: Overall, the observed levels of placebo analgesia in our sample were low and not statistically significant. Levodopa, compared to placebo, only led to a marginal increase in placebo analgesia. Female participants tended to show larger placebo responses than male participants. Within the female subgroup, levodopa showed small-to-moderate effects on placebo analgesia; however, this effect was not statistically significant. CONCLUSIONS: In summary, the present study could not provide evidence for a placebo augmenting effect of levodopa-enhanced dopamine levels in healthy subjects. Further studies are needed to elucidate whether placebo enhancement can be achieved through dopamine augmentation.
Authors: Sarah C Lidstone; Michael Schulzer; Katherine Dinelle; Edwin Mak; Vesna Sossi; Thomas J Ruth; Raul de la Fuente-Fernández; Anthony G Phillips; A Jon Stoessl Journal: Arch Gen Psychiatry Date: 2010-08
Authors: Raúl de la Fuente-Fernández; Anthony G Phillips; Mariangela Zamburlini; Vesna Sossi; Donald B Calne; Thomas J Ruth; A Jon Stoessl Journal: Behav Brain Res Date: 2002-11-15 Impact factor: 3.332
Authors: Katia Monte-Silva; David Liebetanz; Jessica Grundey; Walter Paulus; Michael A Nitsche Journal: J Physiol Date: 2010-07-26 Impact factor: 5.182
Authors: Susanne Becker; Marta Ceko; Mytsumi Louis-Foster; Nathaniel M Elfassy; Marco Leyton; Yoram Shir; Petra Schweinhardt Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Aleksandrina Skvortsova; Dieuwke S Veldhuijzen; Henriët van Middendorp; Luana Colloca; Andrea W M Evers Journal: J Pain Date: 2019-09-05 Impact factor: 5.820